Last reviewed · How we verify
NCT07328113
Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients
trial testing Thyroid hormone in Chronic Kidney Disease on Hemodialysis in 65 participants. Completed in 30 June 2024.
31 March 2024
Quick facts
| Lead sponsor | Dr. Soetomo General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 65 |
| Start date | 14 November 2023 |
| Primary completion | 31 March 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Thyroid hormone — full drug profile →
Conditions studied
- Chronic Kidney Disease on Hemodialysis — all drugs for Chronic Kidney Disease on Hemodialysis →
- Thyroid Gland Disease — all drugs for Thyroid Gland Disease →
Sponsor
Dr. Soetomo General Hospital
Who can join
21 and older, any sex, with Chronic Kidney Disease on Hemodialysis or Thyroid Gland Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic kidney disease (CKD) is often associated with multiorgan complications, including thyroid hormone dysfunction. Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been proposed as a marker of inflammation that may contribute to these alterations. The main question it aims to answer is: Is there an association between interleukin-6 and thyroid hormone dysfunction in patients with chronic kidney disease (CKD) Blood samples will be collected and analyzed from 65 patients who have undergone hemodialysis for at least 3 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07328113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thyroid hormone
Trials testing the same drug.
- NCT01557504 — A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-043 · Phase 1 · completed
Other recruiting trials for Chronic Kidney Disease on Hemodialysis
Currently open trials in the same condition.
- NCT07494695 — Experience of Young Adult Kidney Patients Requiring Haemodialysis · active not recruiting
Other Dr. Soetomo General Hospital trials
Trials by the same sponsor.
- NCT06935630 — Comparison of The Effect of 5-MTHF and Folic Acid Supplementation in Increasing Red Blood Cell Folate in Pregnant Women · NA · recruiting
- NCT06259578 — UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study) · EARLY_PHASE1 · unknown
- NCT06272253 — UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects · EARLY_PHASE1 · unknown
- NCT06282692 — INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old · Phase 3 · unknown
- NCT06553417 — Emollient 'Plus' vs Urea 10% for Mild-Moderate Atopic Dermatitis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07328113 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Soetomo General Hospital
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07328113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing